Silver Nanoparticles Show Promise in Overcoming Lung Cancer Therapies' Limitations

Strategic Insights -

A new research study, published in the journal Biomaterials Advances, has explored the potential of silver nanoparticles (AgNPs) in overcoming the limitations of conventional lung cancer therapies. According to the researchers from Jamia Hamdard, AgNPs have shown significant cytotoxic and apoptotic effects in lung cancer cell lines through mechanisms involving gene regulation, reactive oxygen species (ROS) production, and mitochondrial depolarization. The study also highlights the advantages of biosynthesized AgNPs, particularly those derived from plant extracts, which demonstrate enhanced biocompatibility and reduced toxicity.

Key Takeaways:

  • Silver nanoparticles (AgNPs) have shown potential in overcoming multidrug resistance (MDR) and systemic toxicity in lung cancer therapies.
  • AgNPs exhibit significant cytotoxic and apoptotic effects in lung cancer cell lines through mechanisms involving gene regulation, ROS production, and mitochondrial depolarization.
  • Biosynthesized AgNPs, particularly those derived from plant extracts, demonstrate enhanced biocompatibility and reduced toxicity.
  • AgNPs can modulate the tumor microenvironment and inhibit angiogenesis, paving the way for targeted lung cancer therapies.
  • Advances such as functionalized AgNPs and their integration into photodynamic therapy further enhance their therapeutic potential.
  • Challenges related to off-target toxicity and clinical translation remain, and continued research is essential to fully harness AgNPs' potential.
  • The research highlighted the work of Urushi Rehman, Samar Raies, Ayesha Siddiqua, Shadma Wahab, Garima Gupta, Khang Wen Goh, and Prashant Kesharwani from Jamia Hamdard and other collaborators.

Statistics:

  • 18% of all cancer deaths worldwide are attributed to lung cancer (VerticalNews)
  • AgNPs show significant cytotoxic effects in lung cancer cells at a dose-dependent reduction of cell viability (reported in the study)
  • AgNPs can inhibit angiogenesis and modulate the tumor microenvironment (reported in the study)
  • 2025 is the publication year of the research study (published in Biomaterials Advances, Volume 177, Issue 214395)
  • The study was peer-reviewed and published in Biomaterials Advances, a journal from Elsevier (published by Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands)

Sources:

  • VerticalNews, Vertical News Reporter-Staff News Editor, New Delhi, India
  • Biomaterials Advances, "Silver nanoparticles: Forging a new frontline in lung cancer therapy," 2025, Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands
  • NewsRx LLC, "NewsRx. Jamia Hamdard Reports Findings in Nanoparticles (Silver nanoparticles: Forging a new frontline in lung cancer therapy)," Nanotechnology Weekly, July 7, 2025, p 833.